Objective: Thymidine kinase 2 (TK2), a critical enzyme in the mitochondrial pyrimidine salvage pathway, is essential for mitochondrial DNA (mtDNA) maintenance. Mutations in the nuclear gene, TK2, cause TK2 deficiency, which manifests predominantly in children as myopathy with mtDNA depletion. Molecular bypass therapy with the TK2 products, deoxycytidine monophosphate (dCMP) and deoxythymidine monophosphate (dTMP), prolongs the life span of Tk2-deficient (Tk2 -/-) mice by 2-to 3-fold. Because we observed rapid catabolism of the deoxynucleoside monophosphates to deoxythymidine (dT) and deoxycytidine (dC), we hypothesized that: (1) deoxynucleosides might be the major active agents and (2) inhibition of deoxycytidine deamination might enhance dTMP1dCMP therapy. Methods: To test these hypotheses, we assessed two therapies in Tk2 -/-mice: (1) dT1dC and (2) coadministration of the deaminase inhibitor, tetrahydrouridine (THU), with dTMP1dCMP. Results: We observed that dC1dT delayed disease onset, prolonged life span of Tk2-deficient mice and restored mtDNA copy number as well as respiratory chain enzyme activities and levels. In contrast, dCMP1dTMP1THU therapy decreased life span of Tk2 -/-animals compared to dCMP1dTMP. Interpretation: Our studies demonstrate that deoxynucleoside substrate enhancement is a novel therapy, which may ameliorate TK2 deficiency in patients.
manifesting as either isolated chronic progressive external ophthalmoplegia (CPEO) or a generalized myopathy with CPEO plus facial and limb weakness, gradual progression, and, in some cases, respiratory failure and loss of ability to walk in adulthood. 4, 5 Molecular genetics defects in muscle include severe depletion of mtDNA in the infantile-and childhood-onset forms as well as multiple deletions with or without depletion of mtDNA in late-onset patients. We previously reported that molecular bypass therapy using oral administration of the TK2 products, dCMP and dTMP, in our mouse model of TK2 deficiency (Tk2 H126N knock-in [Tk2 -/-] mice) 6 delays onset of molecular and biochemical abnormalities, ameliorates the symptoms, and prolongs the life span of the animals by 2-to 3-fold. 7 We also observed that after administration, dCMP and dTMP were rapidly catabolized to dC and dT, suggesting that nucleosides, rather than nucleotides, are the major active therapeutic agents. Thus, we hypothesize that the increase of the nucleoside substrates enhances residual activity of TK1, TK2, or both, leading to correction of dNTP pool imbalances. Furthermore, dCMP1dTMP treatment increased levels of deoxyuridine in liver, indicating deamination of dC.
To further enhance this therapy, in this study, we have assessed two different approaches. First, because we have hypothesized that nucleosides are the active therapeutic compounds, we have tested the effects of oral dC1dT on the Tk2 H126N knock-in mouse model. Second, we have assessed the effects of coadministration of tetrahydrouridine (THU), an inhibitor of the cytidine deaminase, with dCMP1dTMP to attempt to increase levels of dC. We have observed that oral dC1dT prolongs the life span of mutant animals by restoring mtDNA copy number and respiratory chain enzyme (RCE) activities and levels. In contrast, addition of THU unexpectedly reduces the life span of animals comparing to oral dCMP1dTMP therapy alone. These results reveal a novel nucleoside substrate enhancement therapy, which significantly ameliorates Tk2 deficiency in our mouse model.
Materials and Methods

Mice
Generation and characterization of Tk2 H126N knock-in mice were previously reported. 6 All experiments were performed according to a protocol approved by the Institutional Animal Care and Use Committee of the Columbia University Medical Center (New York, NY) and were consistent with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Mice were housed and bred according to international standard conditions, with a 12-hour light, 12-hour dark cycle and sacrificed at 13 and 29 days of age. Organs (brain, liver, heart, kidney, intestine, and quadriceps muscle) were removed and either frozen in the liquid phase of isopentane, precooled near its freezing point (-1608C) with dry ice. All the experiments were performed in at least 3 mice per group. Both heterozygous and homozygous wild-type mice were considered as a control group (Tk2 1 ) given that no clinical and biochemical differences were previously described.
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Treatment Administration and Experimental Plan
Deoxycytidine monophosphate (dCMP), deoxythymidine monophosphate (dTMP), tetrahydrouridine (THU), deoxycytidine (dC) and deoxythymidine (dT; Hongene Biotechnology, Inc., Morrisville, NC) were administered in 50ll of Esbilac milk formula for small pets (Pet-Ag) by daily oral gavage to Tk2 H126N knock-in mice (Tk2 -/-) and age-matched controls (Tk2
1
). dCMP and dTMP at a dose of 400mg/kg/day (3.2mM) were coadministered with a dose of 100mg/kg/day of THU, whereas dC and dT were administered using two doses, 260 and 520mg/kg/day (3.2 and 6.4mM). All treatments were administered from postnatal day 4 to 29 days. At age 21 days, mice were separated from the mother and the treatment was continued by oral administration. Mutant and control Tk2 1 mice were weighted and observed closely for comparison.
Phenotype Assessment
Body weight was assessed daily, given that it has been previously observed that incapacity of gaining weight is the first sign of disease. 6 To define the degree of safety and efficacy of each therapy, we compared survival time, age at onset of disease, type and severity of symptoms, occurrence of side effects, and proportion of treatment termination attributed to adverse events in treated and untreated Tk2 mice. Behavior, survival time, and body weights of mice were assessed daily beginning at postnatal day 4.
dNTP Pool by Polymerase Extension Assay
Tissues were homogenized on ice in 10 volumes (w/v) of cold MTSE buffer (210mM of mannitol, 70mM of sucrose, 10mM of Tris-HCl [pH 7.5], 0.2mM ethylene glycol tetraacetic acid, and 0.5% bovine serum albumin) and centrifuged at 1,000g for 5 minutes at 48C, followed by three centrifugations at 13,000g for 2 minutes at 48C. Supernatant was precipitated with 60% methanol, kept 2 hours at -808C, boiled 3 minutes, stored at -808C (from 1 hour to overnight), and centrifuged at 20,800g for 10 minutes at 48C. Supernatants were evaporated until dry and pellet was resuspended in 65ll of water and stored at -80 8C until analyzed. To minimize ribonucleotide interference, total dNTP pools were determined as reported. Absorbance of the elutes were monitored at 267nm, and dT and dU peaks were quantified by comparing their peak areas with a calibration curve obtained with aqueous standards. For definitive identification of dT, dU, uracil, and thymine peaks for each sample, we used a second aliquot treated with an excess of purified Escherichia coli TP (Sigma-Aldrich, St. Louis, MO) to specifically eliminate dT and dU. The detection limit of this method is 0.05mmol/l for all nucleosides. Results are expressed as nmol/mg of protein.
Reverse-Transcriptase Quantitative Polymerase Chain Reaction: mtDNA Quantification
Real-time polymerase chain reaction (PCR) was performed with the primers and probes for murine COX I gene (mtDNA) and mouse glyceraldehyde-3-phosphate dehydrogenase (nuclear DNA [nDNA]; Applied Biosystems, Invitrogen, Foster City, CA) as described using the ddCt method in a Step One Plus Real Time PCR System (Applied Biosystems) 8 . mtDNA values were normalized to nDNA values and expressed as percentage relative to wild type (100%).
Mitochondrial Respiratory Chain Protein Levels
Thirty micrograms of whole-brain cerebrum or cerebellum extracts were electrophoresed in an sodium dodecyl sulfate/12% FIGURE :2.
polyacrylamide gel electrophoresis gel, transferred to ImmunBlot polyvinylidene difluoride membranes (Bio-Rad, Hercules, CA), and probed with the MitoProfile Total OXPHOS Rodent WB Antibody Cocktail of antibodies (MitoSciences, Eugene, OR) against CI subunit Ndufb8, CII-30kDa, CIII-Core protein 2, CIV subunit I, and CV alpha subunit. Protein-antibody interaction was detected with peroxidase-conjugated mouse antimouse immunoglobulin G antibody (Sigma-Aldrich), using the Amersham ECL Plus western blotting detection system (GE Healthcare Life Sciences, Little Chalfont, UK). Quantification of proteins was carried out using National Institutes of Health (NIH) ImageJ software (1.37V; NIH, Bethesda, MD). Average gray value was calculated within selected areas as the sum of the gray values of all the pixels in the selection divided by the number of pixels.
Mitochondrial RCE Activities by Spectrophotometer Analysis
Mitochondrial RCE analysis was performed in cerebrum tissue as previously described.
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Statistical Analysis
Data are expressed as the mean 6 standard deviation (SD) of at least three experiments per group. For data grouped in columns, the Mann-Whitney U test was used to compare each group. A p value of <0.05 was considered to be statistically significant. For survival curves, the Mantel-Cox test was used to compare groups.
Results
Oral dC/dT Delays Disease Onset and Prolongs Mice Life Span
Mice treated with oral dC1dT (260 or 520mg/kg/day, which are molar equivalents of 400 and 800mg/kg/day of dCMP1dTMP, from age 4 days) appeared normal until postnatal day 21. After age 21 days, mutant mice treated with the 260-mg/kg/day dose (Tk2 -/-260 dC1dT )
stopped gaining weight and developed mild head tremor and weakness that led to death at postnatal day 31 6 4 ( Fig 1A,B) . Mutant mice treated with the 520-mg/kg/day dC1dT (Tk2 -/-520 dC1dT ) continued to gain weight for 1 additional week, but after age 28 days deteriorated, similar to Tk2 -/-260 dC1dT after age 21 days and died at postnatal day 43 6 10. The extended life spans of Tk2 mutant mice treated with dC1dT at 260 and 520mg/kg/ day are comparable to those of Tk2 -/-mice treated with 200 or 400mg/kg/day of oral dCMP1dTMP treatment. 7 Treated control mice, Tk2 1 260 dC1dT and Tk2 1 520 dC1dT , followed until postnatal day 60 showed no significant changes in growth or other side effects (Fig 1C,D) .
In contrast, coadministration of oral dCMP 1dTMP (400mg/kg/day) with THU (100mg/kg/day) significantly reduced the mean life span of mutant animals (Tk2 -/-400 dCMP1dTMP1THU ) to 30 6 1 days, compared to 44 6 7 days of survival of Tk2 -/-400 dCMP1dTMP mice (p 5 0.007; Fig 1A) . ). In contrast, deficiencies of dTTP in brain and dCTP in liver remained severe despite nucleoside supplementation (Fig 2A) In Tk2
-/-520 dC1dT mice at postnatal day 13, treatments prevented mtDNA depletion in heart, liver, kidney, intestine, and muscle (Fig 2B) . In contrast, mtDNA copy numbers in brain were only partially ameliorated by these treatments at postnatal day 13, with the mtDNA/nDNA ratio reaching only 39 6 0.3% in Tk2
-/-400 dCMP1dTMP1THU (p < 0.057), 50 6 7% in Tk2 -/-260 dC1dT (p 5 0.009), and 52 6 9% in Tk2 -/-520 dC1dT (p < 0.0001), in contrast to 15 6 7% in untreated Tk2 -/-(p 5 0.030). Measurements of deoxythymidine and the base uracil in brain at postnatal day 13 by HPLC showed higher levels in animals treated with dC1dT and dCMP1dTMP (Fig 3A) , further indicating that dT and probably dC cross the blood-brain barrier. 
Tk2
-/-520 dC1dT in heart (40 6 3% and 35 6 9%), liver (46 6 7% and 45 6 12%), kidney (38 6 8% and 42 6 7%), and muscle (24 6 6% and 35 6 6%), but was more strikingly rescued in intestine (82 6 3% and 84 6 10%; Fig 2B) . Furthermore, mtDNA copy number measured in near-terminal Tk2 -/-520 dC1dT animals showed that mtDNA levels were decreased in all tissues (ranging from 12 6 5% in muscle to 31 6 7% in kidneys) except intestine (86 6 8%; Fig 3B) .
Oral dC1dT Ameliorates Biochemical Abnormalities in Brain
To assess the effects of partially rescued mtDNA levels in brain on mitochondrial function, we measured RCE activities by biochemical assays as well as RCE protein levels by western blot. At postnatal day 13, we observed that both Tk2 -/-260 dC1dT and Tk2 -/-400 dCMP1dTMP1THU significantly increased complex IV activity to levels similar to those showed by The increases in RCE levels and activities in brain likely accounts for the prolonged survival observed with the higher dose of deoxynucleosides.
Discussion
Mitochondrial depletion syndrome (MDS) is defined by a reduction of mtDNA copy number causing secondary deficiencies of respiratory chain complex proteins and activities in target tissues. MDS was first described in 1991 15 and encompasses a phenotypically heterogeneous group of disorders that includes myopathic, encephalomyopathic, and hepatocerebral forms. Interestingly, there are general correlations between the genotypes and phenotype. The myopathic form of the MDS is caused by mutations in TK2, hepatocerebral diseases are attributed to mutations in DGUOK, POLG, C10orf2, or MPV17, muscle and nephropathy attributed to RRM2B, encephalomyopathy attributed to SUCLA2 or SUCLG1, and severe infantile encephalomyopathies attributed to mutations in OPA1 or MFN2. 16, 17 The majority of these genes are required for mtDNA replication or in deoxynucleotides metabolism, 17, 18 which demonstrates the critical role of dNTP pool balance in mtDNA maintenance. While manifesting predominantly as skeletal myopathy, TK2 mutations have presented with other phenotypes, including encephalomyopathy and chronic progressive external ophthalmoplegia. [1] [2] [3] [4] [5] The reason for the phenotypic diversity is not understood and appears not to be attributed to severity of TK2 deficiency. 19 To characterize the pathogenesis and develop therapies for TK2 deficiency, we previously generated a mouse model of TK2 deficiency (Tk2 H126N knockin mice), 6 which recapitulates the encephalomyopathic form of TK2 deficiency. We reported success of a molecular bypass therapy, oral dCMP and dTMP, in our Tk2 mouse model. Doses of 200 and 400mg/kg/day of each deoxynucleoside monophosphate (dNMP) delayed the disease onset and prolonged the life span of animals. 7 Despite the clear benefits of this therapy, we observed that most of the dCMP and dTMP were rapidly converted to their respective nucleosides, dC and dT, suggesting that these nucleosides were the active therapeutic agents. In support of our hypothesis, a study of mitochondria isolated from hearts of rats treated with radiolabeled dT and dTMP demonstrated that most of the mitochondrial TTP was generated from dT, rather than dTMP, and that exogenously administered dTMP was compartmentalized from dTMP synthesized from dT. 20 In the present study, we initially tested a dose of 260mg/kg/day of dC1dT, which is the equimolar concentration of 400mg of dCMP1dTMP, and subsequently 520mg/kg/day of dC1dT. Interestingly, we observed that Tk2 -/-260 dC1dT mice had a life span equivalent to that of , whereas Tk2 -/-520 dC1dT had a life span equivalent to that showed by Tk2 -/-400 dCMP1dTMP . Thus, double the molar amounts of nucleoside relative to dNMPs were required in order to achieve the same prolongation of life span. The reason for the different dose responses to dNMPs relative to deoxynucleosides is unclear. One potential explanation is that, whereas dC1dT functions as the active therapeutic agents as substrates enhancing Tk1, deoxycytidine kinase (Dck), and Tk2 activities, monophosphates may partially bypass the enzyme activity and partially function as prodrugs with conversion to nucleosides, as indicted by Kamath et al. 20 Furthermore, 5 0 -nucleotidase activity might delay the release of dC/dT in tissues, improving dNMP efficacy relative to deoxynucleosides. Another possibility, based on HPLC data, is that further degradation of dC and dT to their bases limits their availability in tissues.
We subsequently tested the effect of dCMP1dTMP therapy coadministered with THU, to decrease the catalytic conversion of dC to dU, thus providing Tk2 with higher levels of dC. An in vitro study showed that THU partially prevented catabolism of dC and mtDNA depletion in a cell-culture model of MNGIE whereas in vivo a single dose of 100mg/kg increased levels of dC in blood in a double-knockout MNGIE mouse model. 21 Unexpectedly, in our mouse model of TK2 deficiency, median life span of animals on dCMP1dTMP1THU therapy was significantly shorter than that of Tk2 -/-mice receiving dCMP1dTMP therapy alone. This result is likely attributed to the lowering of dTTP levels and more-severe mtDNA depletion in brain mitochondria when THU is coadministered with dCMP1dTMP in contrast to dCMP1dTMP treatment. By comparison, addition of THU did not significantly alter levels of dTTP, dCTP, or mtDNA copy number in liver. From these observations, we may conclude that THU exacerbates the dNTP pool imbalance in brain, which, in turn, shortens life span. We hypothesize that, in brain, conversion of dC to dU by cytidine deaminase (CDA) increases levels of intramitochondrial dTTP through TK1 and TS enzyme activities (Fig 8) whereas inhibition of CDA by THU decreases intramitochondrial dTTP levels and accelerates demise of mice.
Our results with dC1dT therapy demonstrated tissue-specific effects of this therapy; intramitochondrial levels of dCTP in brain and dTTP in liver showed early corrections at postnatal day 13 (reduced dCTP in brain and increased dTTP in liver) that were sustained until postnatal day 29; however, levels of dCTP in liver and dTTP in brain remained low at both time points. Hypothetically, thymidine phosphorylase (TP) activity in brain and deaminase activity in liver could account for these tissue-specific effects; however, TP activity is high in liver and low in brain. 16 Furthermore, coadministration of dCMP1dTMP and THU, which inhibits CDA, did not ameliorate dCTP defects in liver at postnatal day 13, despite published reports of THU efficacy in vivo. 22, 23 Taken together, these observations indicate the existence of tissue-specific alternative pathways of nucleosides catabolism and the necessity of further studies to better define nucleotide metabolism.
Measurement of mtDNA levels revealed an additional tissue-specific effect of the substrate enhancement therapy. Both nucleoside monophosphate and nucleoside treatments failed to fully rescue the mtDNA copy number in brain at postnatal day 13, although both therapies showed higher levels of dT and uracil (a catabolic product of dC) in brain at this time, measured by HPLC. We had previously speculated that formation of the blood-brain barrier might compromise bioavailability of nucleoside monophosphates in brain 7 ; however, equilibrative nucleoside transporters 1 and 2 (ENT1 and ENT2), expressed in blood-brain barrier endothelial cells and blood-cerebrospinal fluid barrier epithelial cells, can transport both dT and dC from blood to the brain. 24, 25 Thus, increased enzymatic catabolism during brain maturation, rather than blood-brain barrier formation, may impair efficacy of deoxynucleoside and deoxynucleotide therapies. Similarly, in muscle and liver, deoxynucleosides prevented mtDNA depletion at postnatal day 13, but not at day 29. In contrast, 520mg/kg/day of deoxynucleosides maintained normal mtDNA levels in intestine to the terminal stage, indicating that oral treatment provides higher intestinal bioavailability of dC1dT relative to other tissues. Intraperitoneal administration of the drugs may increase their bioavailability and beneficial effects; however, further studies are required in order to assess this possibility.
Because pyrimidine metabolism involves multiple pathways, other mechanisms may be contributing to tissue-specific efficacy, including nucleoside transport and activities of other catabolic enzymes. In this context, it is noteworthy that TK2 is a complex enzyme and exhibits different kinetics for each substrate (Michaelis-Menten for dC phosphorylation and negative cooperativity for dT phosphorylation). 26 These factors may also influence tissue-specific and long-term efficacy of dC1dT therapy. This is the first demonstration of in vivo effectiveness of nucleosides treatment for mtDNA depletion syndrome. Manipulation of mitochondrial dNTP pool by addition of nucleosides may be an effective therapy not only in cases of TK2 deficiency, but also in other mtDNA depletion syndrome attributed to mitochondrial dNTP pool imbalance.
In conclusion, our results reveal a novel nucleoside therapy and refute the hypothesized therapeutic effect of THU for TK2 deficiency. Oral administration of dC1dT demonstrated benefits previously observed with dCMP1dTMP treatment and appears to be well tolerated and easily translated to patients, indicating that this substrate enhancement therapy may retard progression of this devastating disease in patients. 
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